precisionmedicineonline7h
BMS Seeking FDA Approval for Opdivo-Yervoy in Frontline MSI-High, dMMR Advanced Colorectal Cancer
The firm submitted data from a Phase III study showing the combination improved outcomes compared to Opdivo and chemo alone.
Targeted Oncology9h
FDA Accepts sBLA for Nivolumab/Ipilimumab Combo in dMMR/MSI-H CRC
Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...
Contract Pharma10h
FDA Accepts Bristol Myers Squibb’s sBLA for Opdivo Plus Yervoy
The application was based on results from the three-arm Phase 3 CheckMate -8HW study.